Disadvantages of VKA and requirements for novel anticoagulants

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 2, 2013, Pages 103-114

  Shameem, Raji ^a   Ansell, Jack ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

apixaban; dabigatran; oral anticoagulation; rivaroxaban; vitamin K antagonists; warfarin

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; CLARITHROMYCIN; CYTOCHROME P450 3A4; DABIGATRAN ETEXILATE; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; VERAPAMIL; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DYSFUNCTION; LIVER TOXICITY; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 84882262845     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.07.009     Document Type: Review

References (46)

1. J. Weitz New oral anti-coagulants: which one should my patient use? Hematol Am Soc Hematol Educ Program 2012 536 540
2. A. Choonara The relationship between inhibition of vitamin K 2-3 epoxide reductase and reduction of clotting factor activity with Warfarin Br J Clin Pharmac 25 1998 1 7
3. M. Fasco Evidence that warfarin anticoagulant action involves two distinct reductase activities J Biol Chem 257 19 1982 11210 11212
4. J. Ansell Pharmacology and management of the vitamin K antagonists American College of Chest physicians evidence-based clinical Guidelines (8th edition) Chest 133 6 2008 162S 198S
5. J. Ansell Will the new target-specific oral anticoagulants improve the treatment of venous thromboembolism? Thromb Haemostasis 107 6 2012 1009 1011
6. M. Patel Rivaroxaban versus warfarin in non-valvular atrial fibrillation NEJM 365 2011 883 889
7. C. Granger Apixaban versus warfarin in patients with atrial fibrillation NEJM 365 2011 981 992
8. M. Kim A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity J Clin Pharmacol 49 2009 138 146
9. J. Carlquist Using pharmacogenetics in real time to guide warfarin initiation: a clinician update Circulation 124 2011 2554 2559
10. W. Ageno Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis American College of Chest physicians evidence-based clinical Guidelines (9th edition) CHEST 141 2 2012 44S 88S
11. A. Holbrook Systematic overview of warfarin and its drug and food interactions Arch Intern Med 165 2005 1096 1106
12. Y. Lurie Warfarin and vitamin K intake in the era of pharmacogenetics Br J Clin Pharm 70 2010 164 170
13. M. Cushman The association of vitamin K status with warfarin sensitivity at the onset of treatment Br J Haem 112 2001 572 577
14. W. Chow Anticoagulation instability with life-threatening complication after dietary modification Postgrad Med J 66 1990 855 857
15. I. Ogilvie Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 2010 638 645
16. A.J. Rose Risk-Adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affair Study to Improve Anticoagulation (VARIA) Circ Cardiovasc Qual Outcome 4 2011 22 29
17. W. Baker Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 3 2009 244 252
18. S. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non- valvular atrial fibrillation (SPORTIF III) randomized controlled trial The Lancet 362 2003 1691 1698
19. J. Fisessinger Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis a randomized trial JAMA 293 2005 681 689
20. S. Schulman The oral thrombin inhibitor dabigatran: strengths and weaknesses Semin Thromb Hemost 38 2012 7 15
21. R. Kreutz Pharmacodynamic and pharmacokinetic basic of rivaroxaban Fundam Clin Pharmacol 26 2012 27 32
22. J. Weitz New oral anticoagulants: which one should my patient use? Am Soc Hematol 2012 536 540
23. M. Myer The mechanism of action of rivaroxaban, oral direct factor Xa inhibitor-compared with other anticoagulants Thromb Res 127 2011 497 504
24. P. Rathasen The role of apixaban for venous and arterial thromboembolic disease Ann Pharmacother 45 2011 1262 1282
25. S. Connolly Dabigatran versus warfarin in patients with atrial fibrillation NEJM 361 2009 1139 1151
26. S. Schulman Dabigatran versus warfarin in the treatment of acute venous thromboembolism NEJM 36 2009 2342 2352
27. G. Landman Oral rivaroxaban for symptomatic venous thromboembolism NEJM 364 36 2011 2499 2510
28. R. Bauersachs Oral rivaroxaban for the treatment of symptomatic pulmonary embolism NEJM 366 14 2012 1287 1297
29. S. Schulman How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch Blood 119 2012 3016 3023
30. H. Graeme Dabigatran etexilate a new oral thrombin inhibitor Circulation 123 2011 1436 1450
31. K. Liesenfeld Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with nonvalvular atrial fibrillation from the RE-LY trial J Thromb Haemost 9 11 2011 2168 2175
32. Xarelto Summary of Product Characteristics. www.xarelto-us.com. (Accessed January 2013).
33. D. Kubitza Absence of clinically relevant interactions between rivaroxaban-an oral director factor Xa inhibitor J Int Med Res 40 2012 1688 1707
34. S. Connolly Apixaban in patients with atrial fibrillation NEJM 364 2011 806 817
35. J. Ansell New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation Circulation 125 2012 165 170
36. D. Kubitza The Effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban-an oral direct factor Xa inhibitor Blood (ASH Annu Meet Abstracts) 2006 Abstract 905
37. V. Pengo Questions and answers on the use of dabigatran and perspectives on the use of the use of other new oral an- ticoagulants in patients with atrial fibrillation Thromb Haemostasis 106 5 2011 868 876
38. M. Samama Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor Thromb Hae- mostasis 103 2010 815 824
39. J. Freeman Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11
40. S. Lee Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation PLOS ONE 7 2012 1 9
41. S. Lee Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation Am J Cardiol 10 2012 845 851
42. J. Walenga Drug and dietary interactions of the new and emerging oral anticoagulants Int J Clin Pract 64 2010 956 967
43. J. Van Ryn Dabigatran etexilate- a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemostasis 103 6 2012 1116 1127
44. S. Kaatz Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors Am J Hematol 87 2012 S141 S145
45. A. Waterman Effect of warfarin non-adherence on control of the international normalized ratio Am J Health Syst Pharm 61 2004 1258 1264
46. A. Platt Risk factors for nonadherence to warfarin; results from the IN-RANGE study Pharmacoepidemiol Drug Saf 12 2008 853 860